First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued

First Tracks Biotherapeutics is a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases. The company was separated from AnaptysBio in April 2026 and now trades independently on Nasdaq. Its lead candidate, ANB033, is a CD122 antagonist in Phase 1b development for celiac disease and eosinophilic esophagitis, with plans to expand into additional indications. The pipeline also includes ANB101, a BDCA2 modulator that completed Phase 1a in healthy volunteers with potential applications in lupus, and rosnilimab, a pathogenic T cell depleter being evaluated for rheumatoid arthritis. The company is pre-revenue, funding operations through its cash reserves, and has no approved products on the market. Updated Aug 12, 2026